行业新闻

原文：
Edwards Lifesciences Corporation (EW) has reported earnings per share (EPS) of 48 cents in second quarter fiscal 2010 beating both the Zacks Consensus Estimate of 44 cents and the year-ago quarter’s earnings of 41 cents. However, after adjusting for certain items, the company’s EPS cameResilient Seated Gate Valves in at 46 cents compared with 40 cents in the second quarter of 2009. Edwards reported revenues of $365.2 million, up 8.9% from the year-ago period. However, the growth rate would be 14.8% excluding the impact of foreign exchange movement (forex), discontinued products and previous year’s return of repair products. Segments Heart Valve Therapy remained the strongest segment at Edwards with an annualized growth of 18% to $214.8 million. Sales of surgical heart valves grew 5.5% (on adjusted basis), while that of transcatheter heart valves (THV) doubled year over year to $53.2 million. The launch of Sapien XT valve in EuropeButterfly Valves was primarily responsible for the growth. Edwards has witnessed increased acceptance of Sapien XT products with its NovaFlex (transfemoral) delivery system. We also note that at the end of the quarter, the company began the launch of Sapien XT with its Ascendra 2 (transapical) delivery system. The launch of these products should boost sales of heart valves in the forthcoming period, which is justified by Edwards’ raised THV sales guidance for 2010. The company expects these products to generate sales of $190-$205 million compared to the previous guidance of $170–$190 million. Other segments of the company, Critical Care, Cardiac Surgery SystemsPlug Valves and Vascular recorded sales of $110.5 million (down 2.2%), $26.5 million (up 10%) and $13.4 million (down 17.8%), respectively. The primary reason for the decline in Critical Care segment was the divestment of the hemofiltration product effective September 2009. Excluding the impact of the divestment ($12.3 million) and forex, this segment recorded a growth of 7.7%. The divestment of LifeStent product line was responsible for the decline in Vascular sales. Expenses During the quarter, Edwards’ gross margin improved 290 basis points to 72.5% driven by an improved product mix and manufacturing efficiency, to some extent. The launch of THV led to a 9.4% rise in selling, general and administrative expenses to $140.6 million. The company is continuing its investments inSafety Relief Valves the THV program, which led to an 18.8% rise in research and development (R&D) expenses to $50.6 million. R&D expenses as a percentage of sales increased to 13.9% from 12.7% in the year-ago quarter. Robust Growth in Japan Edwards generated 40% of its revenues during the quarter from the domestic market. Barring the domestic market, which recorded a marginal 0.8% growth in sales, robust growth was witnessed in Needle & Gauge Valves Europe (13.2% to $116.1 million), Japan (15.5% to $60.5 million) and Rest of World (18.6% to $43.9 million). Balance Sheet Edwards exited the quarter with cash and cash equivalents of $320.3 million, down from $334.1 million at the end of December 2009. In May 2010, the company split its shares in the ratio of 2:1. On a post-split basis, the company repurchased $101.3 million worth of shares during the quarter.
原文来自： http://www.nytimes.com/1981/12/26/opinion/escape-valve.html

CHELSEA OIL LEAK LINKED TO TAMPERING WITH VALVES;是由上海日美阀门制造有限公司提供的阀门新闻，中文译文仅供参考，以下提供站内导航搜索：

中国球阀网球阀产品球阀知识球阀厂商球阀博客球阀行业新闻

以下是参考译文：

译文：爱德华兹队胜强阀门销售
爱德华兹兹利费斯西恩西斯公司（东西向）报告每股收益（EPS）48美分，2010财年真空泵第二季度的萨克斯都跳动一致估计的44美分和41美分，而去年同期的收入。然而，某些项目开始后，该公司的每股收益为46美分，调整比40在2009年第二季度美分。爱德华兹报告三亿六千五百二十○万美元收入，同比增长8.9％，由去年同期。但是，其增长幅度消防泵将不包括14.8％的外汇波动的影响（外汇），停产的产品和上一年的修复产品的回报。段治疗心脏瓣膜在爱德华兹仍是最强的部分为18％，年均增长二亿一千四百八万美元。心脏瓣膜手术销售增长5.5％调整为基础（），而经导管心脏瓣膜（THV）较上年同期翻了一番，达到320万美元。该阀在欧洲Sapien的XT的推出主要是为经济增长负责。爱德华兹曾目睹增加其NovaFlex Sapien的XT的（经股）传输系统产品的接受程度。我们还注意到，在本季度末，该公司开始与Ascendra 2（transapical）传输系统的Sapien的XT的推出。这些产品的推出将推动该今后一段时间，这是由爱德华兹的理由心脏瓣膜的销售提出THV 2010年销售预期。该公司预计这些产品的销售产生190美元 - 2.05亿美元，至170美元前指导 - 1.9亿美元。该公司，急救，心脏外科和血管系统的其他部分录得1.105亿美元（下降2.2％），2650万美元（增长10％）和1340万美元（下降17.8％），分别销售。为在急救段下降的主要原因是该产品出售的有效滤过2009年9月。不包括已化工泵出售（1230万美元）和外汇的影响，这部分录得7.7％的增长。该生产线的LifeStent撤资是为在血管销售下降的责任。开支在本季度中，爱德华兹的毛利润率提高290个基点至72.5％由改善产品结构和生产效率驱动，在一定程度上。发射的THV导致了销售上升9.4％，一般及行政开支一四零六零零零零零美元。该公司计划继续在THV，从而导致在研究与发展（R＆D）的费用060万美元增长18.8％的投资。作为一个销售比例的研发费用上升至13.9％，由12.7％，而去年同期。日本经济增长强劲爱德华兹在第二季度产生的从国内市场40％的收入。除非国内市场，录得轻微0.8％，销售额排污泵的增长，强劲的增长见证了欧洲（13.2％至一一六一○○○○○美元），日本（15.5％至6 050万美元）和世界其它地区（18.6％，至4 390万美元）。资产负债表爱德华兹退出了现金及现金等值季度三亿二千〇三十零万美元，低于三三四一〇〇〇〇〇美元于离心泵 2009年12月结束。在2010年5月，该公司在分裂的2:1比例的股份。在一个后分裂的基础上，该公司回购1.013亿美元在该季度的股票。

更多新闻

一旦发生液化气泄露一定要先把总阀关闭

核电站关键阀门技术指标达到国际同类产品水平

开始关闭以及对泄漏阀门和监测情况

英国石油公司的油站阀门关闭墨西哥湾流